Search vesugen benefits and you get a tidy list: blood vessels, blood pressure, brain blood flow, aging. Each item on that list came from somewhere. Almost every one came from a rat, a cell dish, or a different peptide entirely.
The short answer. Every published Vesugen benefit traces to a rat study, a cell study, or another peptide.
- Sokolova's 2016 and 2018 papers measured vessel density and microcirculation in rat brain cortex, not symptoms.
- The Alzheimer's paper is molecular-genetic. It did not treat patients or measure cognition.
- Randomized human trials of KED number zero, and no human pharmacokinetic data is published.
Vesugen is a 3-amino-acid peptide, Lys-Glu-Asp. Randomized human trials number zero. The benefit claims trace to rat and cell studies. Two papers counted blood vessels in rat brain cortex. One Russian lab wrote about 10 of the 12 KED papers. No study we found measured blood pressure in people.
What benefits is Vesugen sold for?
The claim set is consistent across sellers. It is short enough to write out in full.
- Vascular health. Repair or support of blood vessel walls.
- Better microcirculation. More small vessels, better blood flow.
- Endothelial renewal. The cells lining vessels divide again.
- Brain support. Blood flow to the cortex, sometimes framed as memory.
- Anti-aging. Part of a peptide program said to slow aging itself.
- Blood pressure and cholesterol. The vaguest claim, and the one with the least behind it.
Vesugen is a single peptide, not a blend. So there is no ingredient list to hide behind. Every claim should point at one paper. Most of them point at a rat.
The background on sequence, origin and legal status sits in the Vesugen complete guide. This page only does the tracing.
Which study holds which claim
Here is the whole published basis, claim by claim. The middle column is the paper. The right column is what the paper actually measured.
| Claim | Source it traces to | Model | What was measured |
|---|---|---|---|
| Improves microcirculation | Sokolova et al., 2016 | Aged rats | Density of the microvascular network in brain cortex |
| Effect builds with repeated use | Sokolova et al., 2018 | Spontaneously hypertensive rats | Microcirculation in brain cortex |
| Renews endothelial cells | Khavinson et al., 2015 | Vascular endothelial cells | Proliferation and epigenetic regulation |
| Brain and memory support | Khavinson et al., 2021 | Neurogenesis models | Molecular-genetic regulation, Alzheimer's context |
| Slows aging | Anisimov & Khavinson, 2009 | Review of the wider program | Other peptide preparations, not KED alone |
| Lowers blood pressure or cholesterol | No paper located | — | Nothing |
Read the Model column again. Not one row says a person. The strongest claims on a Vesugen label are rat claims, and the weakest claim has no row at all.
The rat studies: what was actually measured
Two papers carry the vascular benefit, and they come from the same group in Saint Petersburg. Sokolova and colleagues published the first in Bulletin of Experimental Biology and Medicine in 2016.
Its title is the claim and its limit in one line:
Effects of vascular peptide bioregulator on the density of microvascular network in the brain cortex of aged rats.
Sokolova, Ryzhak, Mel'nikova, Sergeev & Khavinson, Bulletin of Experimental Biology and Medicine, 2016The outcome was vessel density in cortex tissue. Not blood pressure. Not cholesterol. Not a symptom. And the subject was an aged rat.
The 2 related papers share a design. The 2018 follow-up in Advances in Gerontology used spontaneously hypertensive rats, a strain bred to develop high blood pressure, and looked at whether repeated courses stacked. The word in the title is cumulation, not cure.
That is a real finding in a real model. It is also the ceiling of the evidence. Rodent cortical vessel counts do not convert into a human benefit without several methodological steps that nobody has published.
Vesugen
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
The cell and gene papers
Two more papers sit under the renewal and brain claims, and both are laboratory work.
The 2015 paper in Advances in Gerontology is where the endothelial claim starts. It is about peptidergic regulation of vascular endothelial cell proliferation in aging, studied at the level of gene expression. Cells in culture divide. That is the result.
The 2021 follow-up in Bulletin of Experimental Biology and Medicine is the one sellers reach for when they mention the brain:
Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease.
Khavinson, Lin'kova & Umnov, Bulletin of Experimental Biology and Medicine, 2021A title containing the words Alzheimer's disease is not a treatment result. The paper is molecular-genetic. It describes signaling and expression, not patients, not cognition scores, not imaging.
- Gene expression is a mechanism claim. It tells you what a molecule might do, not what it did to anyone.
- Cell culture skips absorption. A peptide added to a dish never had to survive a gut or a bloodstream.
- Same authors, same institute. About 10 of the 12 KED papers come from one group, with only 1 recent independent paper outside it.
The claims that belong to other peptides
The broadest benefit, slowing aging, does not come from a Vesugen study at all. It comes from the reputation of the program Vesugen belongs to.
Anisimov and Khavinson summarized that program in Biogerontology in 2009:
Peptide bioregulation of aging: results and prospects.
Anisimov & Khavinson, Biogerontology, 2009That review covers work running back to the 1970s, close to 50 years of it, across 6+ peptides. The lifespan and tumor work in it was done with other preparations. Lending those results to KED is a marketing move, not a citation.
If a page says Khavinson peptides have decades of aging data and then sells you Vesugen, check which peptide each cited study used. Usually it is not this one.
What has never been measured in people
This is the short section, and it is the important one.
PubMed lists zero Western randomized human trials of KED for 2020 through 2026. We found no published human pharmacokinetics, no placebo-controlled endpoint, and no blood pressure trial.
The molecule is small, around 390 g/mol, which is part of why the oral capsule format exists in Russia. Small is not the same as absorbed. The absorption data for the oral form is not in the published record we can read.
Vesugen is not approved by the FDA or the EMA. Russia permits it. A research vial sold in the US is a research chemical, and the status of any medicine it resembles is not its status. The legality page covers how that line is drawn.
What you can check instead
You cannot verify a benefit that was never tested in a person. You can verify the vial.
- A batch-matched certificate of analysis. Mass spec and HPLC purity, tied to the lot number on the label. How to read one.
- Storage conditions on arrival. Lyophilized powder and reconstituted solution have different needs. See peptide storage temperature.
- Sequence identity. A COA that names Lys-Glu-Asp and a mass near 390 g/mol is checkable. A label that says vascular bioregulator is not.
For handling mechanics, the reconstitution guide and the peptide calculator cover the arithmetic. For how to compare sellers on their paperwork, see buying peptides online.
Vesugen
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Every published Vesugen benefit traces to a rat study, a cell study, or another peptide.
- Sokolova's 2016 and 2018 papers measured vessel density and microcirculation in rat brain cortex, not symptoms.
- The Alzheimer's paper is molecular-genetic. It did not treat patients or measure cognition.
- Randomized human trials of KED number zero, and no human pharmacokinetic data is published.
- The blood pressure and cholesterol claims have no paper under them that we could find.
- About 10 of the 12 KED papers come from a single Saint Petersburg group.
What we're watching
Watch for pages that cite Khavinson peptides as one body of evidence. The lifespan and tumor work in that program used other preparations. Check which peptide each study actually administered before the claim counts for this one.
Frequently asked questions
Does Vesugen have any human trials?
None that we can find. PubMed lists zero Western randomized human trials of KED for 2020 through 2026. The published support is rat and cell-culture work, most of it from one Russian group.
Does Vesugen lower blood pressure?
No study we located measured blood pressure as an outcome. The 2018 Sokolova paper used spontaneously hypertensive rats, but what it reported was microcirculation in the brain cortex. A hypertensive strain is not a blood pressure result.
Is Vesugen approved by the FDA?
No. It is not approved by the FDA or the EMA. Russia permits it. In the US it is sold as a research compound, and that is the status of the vial regardless of what any related medicine is approved for.
Does the Alzheimer's paper mean Vesugen helps memory?
It does not show that. Khavinson, Lin'kova and Umnov published a molecular-genetic paper in 2021 on neurogenesis regulation. It describes gene and signaling activity. There were no patients and no cognitive outcomes.
Why do so many Vesugen sources cite the same lab?
Because about 10 of the 12 KED papers come from Khavinson's Saint Petersburg group, with roughly 1 recent independent paper outside it. Independent replication is the main thing missing from this file.
Is the vascular peptide bioregulator in the rat papers the same thing as Vesugen?
The papers describe a vascular peptide bioregulator rather than a brand name. Sellers treat it as KED. That mapping is worth checking yourself, because the paper titles do not make it explicit.
References
- Anisimov, V. N., & Khavinson, V. K. (2009). Peptide bioregulation of aging: Results and prospects. Biogerontology, 11(2), 139–149. https://doi.org/10.1007/s10522-009-9249-8
- Sokolova, I. B., Ryzhak, G. A., Mel’nikova, E. V., Sergeev, I. V., & Khavinson, V. K. (2016). Effects of vascular peptide bioregulator on the density of microvascular network in the brain cortex of aged rats. Bulletin of Experimental Biology and Medicine, 161(4), 569–572. https://doi.org/10.1007/s10517-016-3400-8
- Sokolova, I. B., Ryzhak, G. A., & Khavinson, V. K. (2018). Functional cumulation of the influence of vascular peptide bioregulator on microcirculation in the brain cortex of spontaneously hypertensive rats. Advances in Gerontology, 8(2), 119–123. https://doi.org/10.1134/s2079057018020170
- Khavinson, V. K., Tarnovskaya, S. I., Linkova, N. S., Gutop, E. O., & Elashkina, E. V. (2015). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging. Advances in Gerontology, 5(4), 217–220. https://doi.org/10.1134/s2079057015040116
- Khavinson, V. K., Lin’kova, N. S., & Umnov, R. S. (2021). Peptide KED: Molecular-genetic aspects of neurogenesis regulation in Alzheimer’s disease. Bulletin of Experimental Biology and Medicine, 171(2), 190–193. https://doi.org/10.1007/s10517-021-05192-6
